Medtech Startups: Hyperfine, OPUM Technologies, BioLiberty, & more

Published on Feb 22, 2021


LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape. 

Hyperfine raises $90M in Series D Financing

Hyperfine is the company behind Swoop, an FDA 510(k)-cleared portable MRI machine. Funds from the round will be utilized to accelerate the company’s plans for commercial launch in multiple countries, as well as to aggressively improve the commercial expansion of their technology in the US. In addition to the support of commercialization efforts, the funds will be used to obtain new regulatory clearances, expand uses cases, and improve their technology’s deep learning and AI capabilities. Key strategics in the MRI market include Canon, GE Healthcare, and Siemens.

Start a Free Trial to Medtech Startup Tracker Today

OPUM Technologies is using artificial intelligence to modernize musculoskeletal care

OPUM Technologies’ Digital Knee Platform is a next-generation knee brace that combines continuous patient monitoring with artificial intelligence to provide actionable data and insights to help patients manage recovery and achieve long-term knee health. The platform is suitable for patients recovering from ACL surgery and knee replacement. Furthermore, patients with osteoarthritis or patellofemoral pain can benefit from personalized exercise plans intended to reduce pain and rehabilitate the knee towards pain-free activity. The company has raised an estimated $1.2M in capital to-date through seed funding.

OPUM Technologies is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.

BioLiberty – an assistive platform for patients with hand weakness

Multiple sclerosis, rheumatoid arthritis, and stroke are just a few of the conditions which can result in hand weakness. BioLiberty is developing a glove-like technology, powered by artificial intelligence, for the restoration of hand strength. The company’s platform consists of lightweight robotic gloves that connects to a digital therapy platform that uses machine learning to process digital signals and configure the assistive robotic technology in the gloves. In February 2021, BioLiberty closed its first Seed round of fundraising for an undisclosed amount of funding.

nRichDx is developing a comprehensive liquid biopsy system

The nRichDx Revolution System is being designed as a comprehensive platform for performing liquid biopsies. The technology is initially focused on the detection of cell-free DNA (cfDNA), but will eventually be capable of detecting circulating tumor cells (CTCs), exosomes, cell-free nucleic acids and (cfNA). In addition to being used for the early detection of platform, the company intends to expand applications for the Revolution System, including infectious disease testing and non-invasive prenatal testing. Key competitors in the liquid biopsy market include Biocept, Guardant Health, and Qiagen.

nRichDx is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.

AcuSurgical closes Series A fundraising round for $5.8M

Funds raised will support growth of the company’s team and help the company achieve key milestones towards certification and commercialization of their novel robotics platform. AcuSurgical is developing a robotic system to support vitreo-retinal surgery. The robotic assistant platform will improve the precision and safety of current retinal procedures, and potentially enable new retinal surgeries. The company has signed a partnership with the Adolphe de Rothschild Foundation. Intuitive Surgical, Johnson & Johnson, and Stryker are some of the key strategics in the robotics surgery market.

Precisis – neurostimulation for the treatment of cerebral diseases

The company is developing the EASEE system, a novel and versatile epicranial neurostimulation system. The EASEE system’s transcranial stimulation passes through the cranium to stimulate the targeted regions of the brain, without touching the brain with electrodes. The first indication for the technology is for the treatment of epilepsy, with depression and additional cerebral diseases under investigation for future development. Major strategics in the neurostimulation market include Abbott, Boston Scientific, and Medtronic.

Precisis is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.

Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.

Topics: Medtech, Medtech Venture Capital, Startup, Strategics, Insider, Medtech Innovation Weekly Update

Join us at the next LSI Emerging Medtech Summit

LSI's global events attract top innovators, active investors, and deal-making strategics.


Medtech Pro Free Trial

The only all-in-one market intel platform tracking the market data, companies, & deals shaping medtech.

Companies We Work With